The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
wan qi ru xian ai zhi liao yao kadcyla
Author(s): 
Pages: 247-248
Year: Issue:  4
Journal: JOURNAL OF PHARMACEUTICAL RESEARCH

Abstract:  2013年2月22日,美国食品药品管理局(FDA)批准罗氏集团旗下基因泰克公司的Kadcyla(ado-trastuzumab emtansine)用于治疗HER2阳性晚期(转移性)乳腺癌.在HER2阳性乳腺癌中,HER2蛋白数量的增加可导致癌细胞的生长和生存.Kadcyla用于先前使用曲妥珠单抗、其他抗HER2治疗药物及常用的乳腺癌治疗一线化疗药物紫杉烷类治疗无效的患者.
Related Articles
No related articles found